• +1-646-491-9876
    • +91-20-67278686

    Search

    Drug Addiction - Pipeline Review, H1 2017

    Drug Addiction - Pipeline Review, H1 2017

    • Report Code ID: RW0001689449
    • Category Healthcare
    • No. of Pages 165
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Pipeline Review, H1 2017, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.

    Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 6, 2, 28, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 12 and 5 molecules, respectively.

    Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).
    - The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Publisher Report Coverage 7
    Drug Addiction - Overview 8
    Drug Addiction - Therapeutics Development 9
    Pipeline Overview 9
    Pipeline by Companies 10
    Pipeline by Universities/Institutes 13
    Products under Development by Companies 15
    Products under Development by Universities/Institutes 18
    Drug Addiction - Therapeutics Assessment 20
    Assessment by Target 20
    Assessment by Mechanism of Action 23
    Assessment by Route of Administration 26
    Assessment by Molecule Type 28
    Drug Addiction - Companies Involved in Therapeutics Development 30
    Addex Therapeutics Ltd 30
    Aelis Farma SAS 30
    Aphios Corp 31
    Astraea Therapeutics LLC 31
    BioCorRx Inc 32
    Cerecor Inc 32
    Chiesi Farmaceutici SpA 33
    Curemark LLC 33
    Embera NeuroTherapeutics Inc 34
    F. Hoffmann-La Roche Ltd 34
    Foresee Pharmaceuticals LLC 35
    Heptares Therapeutics Ltd 35
    Immunovaccine Inc 36
    Indivior Plc 36
    InterveXion Therapeutics LLC 37
    Intra-Cellular Therapies Inc 37
    Kyorin Pharmaceutical Co Ltd 38
    Kyowa Hakko Kirin Co Ltd 38
    MedRev Pharma 39
    NLS Pharma Group 39
    Omeros Corp 40
    Opiant Pharmaceuticals Inc 40
    Orexigen Therapeutics Inc 41
    P2D Bioscience 41
    Saniona AB 42
    Savant HWP Inc 42
    Stada Arzneimittel AG 43
    Teva Pharmaceutical Industries Ltd 43
    Zynerba Pharmaceuticals Inc 44
    Drug Addiction - Drug Profiles 45
    (acetaminophen + hydrocodone bitartrate + Respiratory Drug) - Drug Profile 45
    (hydrocodone bitartrate + naltrexone hydrochloride) - Drug Profile 46
    (metyrapone + oxazepam) - Drug Profile 47
    18-MC - Drug Profile 50
    ADX-71441 - Drug Profile 52
    ADX-71743 - Drug Profile 56
    ADX-88178 - Drug Profile 57
    AEF-0117 - Drug Profile 60
    ANS-6637 - Drug Profile 61
    AT-076 - Drug Profile 62
    AT-089 - Drug Profile 63
    AT-1001 - Drug Profile 64
    AT-212 - Drug Profile 65
    Biologic to Agonize TLR4 for Drug Addiction - Drug Profile 66
    cannabidiol - Drug Profile 67
    CERC-501 - Drug Profile 68
    CM-1212 - Drug Profile 71
    dronabinol - Drug Profile 72
    dronabinol - Drug Profile 73
    Drug for Dependence - Drug Profile 74
    Enzyme for Cocaine Addiction - Drug Profile 75
    EORA-101 - Drug Profile 76
    FP-004 - Drug Profile 77
    Gene Therapy to Activate Cocaine Hydrolase for Cocaine Abuse - Drug Profile 78
    h2E-2 - Drug Profile 79
    ibudilast - Drug Profile 80
    istradefylline - Drug Profile 90
    ITI-333 - Drug Profile 93
    IXT-m200 - Drug Profile 94
    JDTic - Drug Profile 96
    JQ-1 - Drug Profile 97
    KDAC-0001 - Drug Profile 98
    levofacetoperane - Drug Profile 99
    lofexidine hydrochloride - Drug Profile 100
    LT-22 - Drug Profile 102
    MC-100093 - Drug Profile 103
    naloxone hydrochloride - Drug Profile 104
    naltrexone hydrochloride SR - Drug Profile 107
    NS-2359 - Drug Profile 109
    OMS-405 - Drug Profile 111
    OMS-527 - Drug Profile 113
    OREX-1019 - Drug Profile 115
    OREX-1038 - Drug Profile 116
    RBP-8000 - Drug Profile 117
    Recombinant Enzyme for Cocaine Abuse - Drug Profile 119
    RO-5256390 - Drug Profile 120
    Small Molecule to Activate Kappa Opioid Receptor for CNS - Drug Profile 121
    Small Molecule to Antagonize Dopamine D1, D2 and D3 Receptors for Cocaine Use Disorder and Schizophrenia - Drug Profile 122
    Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile 123
    Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile 124
    Small Molecules for Neonatal Abstinence Syndrome - Drug Profile 125
    Small Molecules to Agonize 5HT2C and Antagonize 5HT2A, 5HT2B for Psychiatric Disorders - Drug Profile 126
    Small Molecules to Block VMAT2 for Methamphetamine Addiction - Drug Profile 127
    Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile 128
    Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 129
    Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile 130
    Small Molecules to Inhibit Kappa Opioid Receptor for CNS - Drug Profile 131
    Small Molecules to Scavenge Free Radicals for Oxidative Stress Related Disorders - Drug Profile 132
    Small Molecules to Target 5HT2 for CNS Disorders and Obesity - Drug Profile 133
    Small Molecules to Target Nicotinic Acetylcholine Receptors for Drug Addiction and Drug Abuse - Drug Profile 134
    Synthetic Peptide to Target Kappa Opioid Receptors for Drug Addiction - Drug Profile 135
    Vaccine for Cocaine Addiction - Drug Profile 136
    Vaccine for Drug Abuse - Drug Profile 138
    Vaccine for Methamphetamine Abuse - Drug Profile 139
    Vaccine for Methamphetamine Addiction - Drug Profile 141
    VU-0463841 - Drug Profile 142
    Drug Addiction - Dormant Projects 143
    Drug Addiction - Discontinued Products 146
    Drug Addiction - Product Development Milestones 147
    Featured News & Press Releases 147
    Appendix 159
    Methodology 159
    Coverage 159
    Secondary Research 159
    Primary Research 159
    Expert Panel Validation 159
    Contact Us 159
    Disclaimer 160

    List of Tables

    Number of Products under Development for Drug Addiction, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Drug Addiction - Pipeline by Addex Therapeutics Ltd, H1 2017
    Drug Addiction - Pipeline by Aelis Farma SAS, H1 2017
    Drug Addiction - Pipeline by Aphios Corp, H1 2017
    Drug Addiction - Pipeline by Astraea Therapeutics LLC, H1 2017
    Drug Addiction - Pipeline by BioCorRx Inc, H1 2017
    Drug Addiction - Pipeline by Cerecor Inc, H1 2017
    Drug Addiction - Pipeline by Chiesi Farmaceutici SpA, H1 2017
    Drug Addiction - Pipeline by Curemark LLC, H1 2017
    Drug Addiction - Pipeline by Embera NeuroTherapeutics Inc, H1 2017
    Drug Addiction - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Drug Addiction - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
    Drug Addiction - Pipeline by Heptares Therapeutics Ltd, H1 2017
    Drug Addiction - Pipeline by Immunovaccine Inc, H1 2017
    Drug Addiction - Pipeline by Indivior Plc, H1 2017
    Drug Addiction - Pipeline by InterveXion Therapeutics LLC, H1 2017
    Drug Addiction - Pipeline by Intra-Cellular Therapies Inc, H1 2017
    Drug Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
    Drug Addiction - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
    Drug Addiction - Pipeline by MedRev Pharma, H1 2017
    Drug Addiction - Pipeline by NLS Pharma Group, H1 2017
    Drug Addiction - Pipeline by Omeros Corp, H1 2017
    Drug Addiction - Pipeline by Opiant Pharmaceuticals Inc, H1 2017
    Drug Addiction - Pipeline by Orexigen Therapeutics Inc, H1 2017
    Drug Addiction - Pipeline by P2D Bioscience, H1 2017
    Drug Addiction - Pipeline by Saniona AB, H1 2017
    Drug Addiction - Pipeline by Savant HWP Inc, H1 2017
    Drug Addiction - Pipeline by Stada Arzneimittel AG, H1 2017
    Drug Addiction - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
    Drug Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017
    Drug Addiction - Dormant Projects, H1 2017
    Drug Addiction - Dormant Projects, H1 2017 (Contd..1), H1 2017
    Drug Addiction - Dormant Projects, H1 2017 (Contd..2), H1 2017
    Drug Addiction - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Drug Addiction, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Addex Therapeutics Ltd
    Aelis Farma SAS
    Aphios Corp
    Astraea Therapeutics LLC
    BioCorRx Inc
    Cerecor Inc
    Chiesi Farmaceutici SpA
    Curemark LLC
    Embera NeuroTherapeutics Inc
    F. Hoffmann-La Roche Ltd
    Foresee Pharmaceuticals LLC
    Heptares Therapeutics Ltd
    Immunovaccine Inc
    Indivior Plc
    InterveXion Therapeutics LLC
    Intra-Cellular Therapies Inc
    Kyorin Pharmaceutical Co Ltd
    Kyowa Hakko Kirin Co Ltd
    MedRev Pharma
    NLS Pharma Group
    Omeros Corp
    Opiant Pharmaceuticals Inc
    Orexigen Therapeutics Inc
    P2D Bioscience
    Saniona AB
    Savant HWP Inc
    Stada Arzneimittel AG
    Teva Pharmaceutical Industries Ltd
    Zynerba Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//drug-addiction-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//drug-addiction-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//drug-addiction-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments